Navigation Links
Neuronetrix Announces Preliminary Alzheimer's Study Results at the Society for Neuroscience Conference
Date:12/8/2008

LOUISVILLE, Ky., Dec. 8 /PRNewswire/ -- Last week, at the Society for Neuroscience Conference in Washington DC, Neuronetrix announced preliminary results from a clinical study of their COGNISION(TM) System to diagnose Alzheimer's disease. The study was performed with Alzheimer's patients at the University of Kentucky's Sanders-Brown Center for Aging.

The COGNISION(TM) System uses event-related potentials (ERP) to record brain activity while the patient listens to a sequence of sounds. Subjects with Alzheimer's process auditory information differently than healthy individuals and that difference can be detected with the test.

The ability of the ERP method to diagnose Alzheimer's disease has been demonstrated in scientific studies at several research laboratories around the world. In a scientific paper published in 2007, Neuronetrix collaborators Drs. Robi Polikar, et al, reported that their ERP classification accuracy "exceeded that of the trained community clinic physicians, and closely approached the gold standard performance of the university hospital-based clinic evaluation."

This phase of the study was primarily performed to evaluate the COGNISION(TM) System in a real-world clinical setting to test ease of use, patient tolerance, and most importantly, data quality.

"Clinical usability and technical performance were major milestones in our study at the Sanders-Brown Center." "The system exceeded our expectations in terms of data quality and we demonstrated the test could be efficiently performed on real Alzheimer's patients." K.C. Fadem, Neuronetrix, Inc.

The next clinical study phase for Neuronetrix will be to test the COGNISION(TM) System in a multi-center trial on patients who have been diagnosed with Alzheimer's disease using a rigorous diagnostic protocol. This protocol will be similar to that used in the Alzheimer's Disease Neuroimaging Initiative (ADNI), a large international study sponsored by the US National Institutes of Health (NIH).

The ADNI protocol uses psychometric testing, magnetic resonance imaging (MRI), and cerebrospinal fluid analysis (CSF) to accurately characterize several aspects of Alzheimer's disease. Neuronetrix will use these same tests to correlate with the COGNISION(TM) ERP results.

"We want to compare our COGNISION(TM) System with the most advanced diagnostic methods possible to clearly demonstrate the system's capabilities." Dr. John Barker, Chairman, Neuronetrix, Inc.

Neuronetrix is currently working with several NIH Center's of Excellence in the US and a center in Europe to organize the study which is expected to begin in the first quarter of 2009.

About Alzheimer's Disease

Alzheimer's disease is a chronic neurodegenerative disease of the brain which eventually leads to death. Today, Alzheimer's disease affects over 5 million Americans with 500,000 new cases reported each year. The Center for Disease Control recently reported that Alzheimer's disease is the 7th leading cause of death in the US. Those affected by Alzheimer's disease survive only about half as long as those unaffected and of similar age. In 2005, Medicare/Medicaid spending totaled $112 billion on beneficiaries with Alzheimer's and other dementias.

For information: http://www.neuronetrix.com .


'/>"/>
SOURCE Neuronetrix, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
8. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2017)... 2017  Explorers Like Us ( https://explorerslikeus.com/ ) is embarking ... — and deliver these experiences as part of Life Environments™, ... and heal better. ... While nothing beats a walk, jog or simply playing ... Environments™ is the next best thing when getting there isn’t ...
(Date:8/29/2017)... , Aug. 29, 2017 ivWatch, LLC, the leading ... IV infiltrations, announced it has been awarded an Innovative Technology contract ... in the country. ... monitoring device to aid in the early detection of peripheral IV ... The Innovative Technology ...
(Date:8/28/2017)... , Aug. 28, 2017   Aesculight ®, a division of ... surgical lasers. Built on over 20 years of American veterinary laser ... New and Exclusive VetScalpel®Features and Enhancements ... Duclos, DVM, is excising a tumor with his new VetScalpel laser. Dr. ... Lynnwood, WA. ...
Breaking Medicine Technology:
(Date:9/21/2017)... (PRWEB) , ... September 21, 2017 , ... ... **An FDAnews Management Report**, http://www.fdanews.com/products/54818-promotional-communication      , In the competitive world of ... can get while staying in compliance with FDA rules. , The FDA has ...
(Date:9/21/2017)... ... September 21, 2017 , ... ... LVS 7510 at the Global GS1 Healthcare Conference 2017 in Chicago, IL on ... industry for ensuring label quality and improving patient safety. , Microscan ...
(Date:9/21/2017)... , ... September 21, 2017 , ... FlipBelt, the fitness ... attention to detail to the athletic wear market with the launch of their FlipBelt ... can have their essentials securely at their fingertips while at the gym, on the ...
(Date:9/20/2017)... ... 20, 2017 , ... FirstAlign ( http://www.firstalign.com ), combines strategies ... Intelligence (AI) thinking, announced today the launch of its revamped web presence. ... that offers a more comprehensive understanding of the organization’s business and machine learning ...
(Date:9/20/2017)... ... September 20, 2017 , ... ... company specializing in medical device compliance and commercialization, has just released a ... activities. , FDA is more adamant than ever about medical device, pharmaceutical, ...
Breaking Medicine News(10 mins):